Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction

Background and aim:Heart failure with preserved ejection fraction (HFpEF) is associated with an increased risk of heart failure (HF) hospitalizations and cardiovascular death (CVD). Both dapagliflozin and sacubitril–valsartan have recently shown convincing reductions in the combined risk of CVD and...

Full description

Bibliographic Details
Main Authors: Ronen Arbel, Abed N. Azab, Mansi Oberoi, Enis Aboalhasan, Artyom Star, Khaled Elhaj, Fouad Khalil, Hilmi Alnsasra
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Pharmacology
Subjects:
heart failure with mildly reduced or preserved ejection fraction
dapagliflozin
sacubitril–valsartan
cost needed to treat
outcomes
SLGT-2
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1357673/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1357673/full

Similar Items